08:46 AM EDT, 07/29/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Tuesday its Jaypirca treatment met the primary endpoint of non-inferiority in overall response rate compared with Imbruvica in a phase 3 trial for chronic lymphocytic leukemia and small lymphocytic lymphoma.

The company said that a key secondary endpoint of progression free survival wasn't yet mature but that it was trending in favor of Jaypirca.

The safety profile of Jaypirca was similar to that reported in prior studies, and full trial results will be shared at a medical meeting later this year, Eli Lilly ( LLY ) said.

Shares of the company were down 3% in recent Tuesday premarket activity.